1. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report
- Author
-
Lewis B. Silverman, Marie Grosjean, Chirag J. Patel, Wenjian Yang, Morten Tulstrup, Benjamin Ole Wolthers, Rachita Yadav, Eric Larsen, Kjeld Schmiegelow, Thomas Frandsen, Ramneek Gupta, Rachid Abaji, Inge M. van der Sluis, Anja Möricke, Sujith Samarasinghe, Maja Krajinovic, Der-Cherng Liang, Antonella Colombini, Andishe Attarbaschi, Shlomit Barzilai, Gabriele Escherich, Kirsten K. Rasmussen, Martin Stanulla, and Ester Zapotocka
- Subjects
Male ,medicine.medical_specialty ,Asparaginase ,Adolescent ,Genotype ,Trypsinogen ,Antineoplastic Agents ,Gastroenterology ,Models, Biological ,Polymorphism, Single Nucleotide ,Article ,Polyethylene Glycols ,chemistry.chemical_compound ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Genetic predisposition ,PRSS2 ,Humans ,Genetic Predisposition to Disease ,Trypsin ,Trypsinogen activation ,Child ,Childhood Acute Lymphoblastic Leukemia ,Alleles ,Genetic Association Studies ,business.industry ,Genetic Variation ,Infant ,Hematology ,Odds ratio ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Acute Lymphoblastic Leukemia ,Phenotype ,chemistry ,Pancreatitis ,Child, Preschool ,Female ,business - Abstract
Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0−17.9 years treated for acute lymphoblastic leukemia between 2000 and 2016. Cases (n=244) were defined by the presence of at least two of the following criteria: (i) abdominal pain; (ii) levels of pancreatic enzymes ≥3 x upper normal limit; and (iii) imaging compatible with pancreatitis. Controls (n=1320) completed intended asparaginase therapy, with 78% receiving ≥8 injections of pegylated-asparaginase, without developing asparaginase-associated pancreatitis. rs62228256 on 20q13.2 showed the strongest association with the development of asparaginase-associated pancreatitis (odds ratio=3.75; P=5.2x10 -8 ). Moreover, rs13228878 (OR=0.61; P=7.1x10 -6 ) and rs10273639 (OR=0.62; P=1.1x10 -5 ) on 7q34 showed significant association with the risk of asparaginase-associated pancreatitis. A Dana Farber Cancer Institute ALL Consortium cohort consisting of patients treated on protocols between 1987 and 2004 (controls=285, cases=33), and the Children’s Oncology Group AALL0232 cohort (controls=2653, cases=76) were available as replication cohorts for the 20q13.2 and 7q34 variants, respectively. While rs62228256 was not validated as a risk factor (P=0.77), both rs13228878 (P=0.03) and rs10273639 (P=0.04) were. rs13228878 and rs10273639 are in high linkage disequilibrium (r 2 =0.94) and associated with elevated expression of the PRSS1 gene, which encodes for trypsinogen, and are known risk variants for alcohol-associated and sporadic pancreatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin induces autodigestion and pancreatitis. In conclusion, this study finds a shared genetic predisposition between asparaginase-associated pancreatitis and non-asparaginase-associated pancreatitis, and targeting the trypsinogen activation pathway may enable identification of effective interventions for asparaginase-associated pancreatitis.
- Published
- 2019
- Full Text
- View/download PDF